Investment
Features
FeesSafety
Academy
More
Pluang+

Cracker Barrel earnings expected to drop sharply in Q3 2026, with EPS forecast at $0.17 and revenue down.

Company Fundamentals
22 Sep 2026
Rayan Ahmad
View Source
Bearish
Cracker Barrel earnings expected to drop sharply in Q3 2026, with EPS forecast at $0.17 and revenue down.

Cracker Barrel Old Country Store is set to report its Q3 2026 earnings on September 23, with analysts predicting a significant decline. Earnings per share are expected to fall to $0.17 from $0.74 last year, and revenue is forecasted around $834.57 million, down from $868.01 million. Despite the drop, some analysts have raised price targets, reflecting mixed market sentiment. The company maintains a market cap of about $1.03 billion and offers a 2.29% annual dividend yield, which may attract income-focused investors.

Cracker Barrel's upcoming Q3 2026 earnings report is anticipated to show a decline, providing context for market watchers. For readers following the Consumer Cyclical sector, here is Pluang's market snapshot as of Sep 22, 2026 21:33 WIB: out of 111 priced US stocks, 87 rose and 22 fell. Notable moves include Capri Holdings Ltd (CPRI) up 9.99% at USD 15.74 with a typical hold time of 42 days, Dicks Sporting Goods Inc (DKS) rising 6.53% to USD 131.70 but with 100% sell order activity and a hold time of 15 days, and CAVA Group Inc (CAVA) increasing 5.71% to USD 54.97 with 100% buy order activity and an 8-day hold time.

More News

THOR Industries misses Q4 EPS estimates but beats revenue expectations amid RV market challenges

THOR Industries misses Q4 EPS estimates but beats revenue expectations amid RV market challenges

THOR Industries reported Q4 earnings with an EPS of $0.78, missing analyst estimates and showing a 66.9% drop from last year. Despite this, the company beat revenue expectations with $2.31 billion, though revenue declined 8.4% year-over-year due to w...

Company Fundamentals
Bearish
28 minutes ago
Abivax gains FDA nod for Obefazimod, backed by strong cash and positive analyst outlook.

Abivax gains FDA nod for Obefazimod, backed by strong cash and positive analyst outlook.

Abivax received positive pre-NDA feedback from the U.S. FDA for its drug Obefazimod, marking a key step in its development. Despite a recent price target cut by Wedbush to $118, analysts maintain a "Moderate Buy" consensus with an average target of $...

Market News
Bullish
1 hour ago
Netflix stock downgraded by HSBC and Wells Fargo over falling viewer engagement.

Netflix stock downgraded by HSBC and Wells Fargo over falling viewer engagement.

HSBC and Wells Fargo have downgraded Netflix stock due to declining subscriber engagement and an 8% drop in viewership time. Despite a recent 2.19% stock gain, Netflix shares have fallen over 40% in the past year amid strong competition and weaker or...

Market News
Bearish
1 hour ago
FormFactor director sells 2,100 shares, signaling insider stock movement

FormFactor director sells 2,100 shares, signaling insider stock movement

A director at FormFactor sold 2,100 shares, indicating a notable insider transaction. Such sales can reflect personal financial decisions or strategic portfolio adjustments by company insiders. Investors often watch these moves for potential signals ...

Market News
Bearish
1 hour ago
Smiths Group posts strong 2026 earnings, reshapes portfolio to focus on core growth areas

Smiths Group posts strong 2026 earnings, reshapes portfolio to focus on core growth areas

Smiths Group reported solid fiscal 2026 results, meeting EPS and revenue expectations with an EPS of $0.66 and revenue of $1.37 billion. The company improved operating profit, driven by strategic portfolio changes including selling non-core divisions...

Company Fundamentals
Bullish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App